Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum

Healthcare Providers Embrace Blood Volume Analysis (BVA) in Nephrology and Heart Failure Outpatient Care

Oak Ridge, TN, Dec. 18, 2024 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces expansion of its ezBVA Lab service to two new health systems. Daxor’s ezBVA Lab provides cost-effective blood volume analysis, offering comprehensive sample processing with minimal initial investment. The service has broad reimbursement coverage across hospitals and ambulatory care settings.

New wins include:

• A major Arizona-based multi-campus medical center has adopted our BVA technology for outpatient nephrology care with further departments to follow in 2025.
• A regional health network serving communities across Southwest Iowa, Nebraska, Minnesota, and North Dakota has agreed to implement BVA for heart failure outpatient management.

“Our BVA platform is a critical diagnostic tool that redefines outpatient care by providing real-time insights into a patient’s volume status. By enabling early detection of fluid imbalances and cardiovascular risks, BVA empowers clinicians to intervene proactively, potentially preventing costly hospitalizations, reducing emergency interventions, and personalizing patient treatment strategies,” said John Jefferies, Daxor’s Chief Medical Officer.

“The continued sales growth that the company is experiencing has positioned us for our best quarter ever in terms of revenue and year-over-year growth reflecting the focus of our commercialization team and the increasing customer engagement driven by our clinical education team,” said Michael Feldschuh, Daxor’s CEO and President.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^™ (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com